Key Takeaways Abbott's (ABT) Established Pharmaceuticals Division ("EPD") is heavily focused on emerging markets. In the first quarter of 2026, the segment posted 9% year-over-year sales growth, supported by broad-based demand across the markets it serves. Within this, sales in Key Emerging Markets increased 9.4%, including double-digit growth in several countries across Latin America and the Asia Pacific regions. These markets represent compelling growth opportunities for branded generic medicines due to f ...